Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) CFO Kevin Patrick Moran sold 2,239 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $10.97, for a total value of $24,561.83. Following the completion of the sale, the chief financial officer now directly owns 117,452 shares in the company, valued at $1,288,448.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Vanda Pharmaceuticals Price Performance
VNDA opened at $10.54 on Tuesday. Vanda Pharmaceuticals Inc. has a 1-year low of $9.24 and a 1-year high of $21.44. The stock’s 50 day simple moving average is $10.57 and its 200 day simple moving average is $11.42. The stock has a market cap of $595.40 million, a P/E ratio of 32.94 and a beta of 0.47.
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.10). Vanda Pharmaceuticals had a net margin of 6.79% and a return on equity of 3.65%. The business had revenue of $60.19 million for the quarter, compared to the consensus estimate of $58.00 million. During the same period last year, the firm posted $0.15 EPS. Research analysts expect that Vanda Pharmaceuticals Inc. will post 0.3 EPS for the current fiscal year.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 3rd.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.